Novantrone (Mitoxantrone Hydrochloride)

Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This creates double‑strand breaks that trigger apoptosis in rapidly dividing cancer cells. The drug also generates free radicals that add to its cytotoxic effect.

The dose of Novantrone is individualized by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. No fixed regimen is provided in public information.

Novantrone is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated during pregnancy and should not be used by breastfeeding mothers because it can be excreted in milk and may harm the infant.

To request Novantrone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Novantrone shares the DNA‑intercalating and topoisomerase II‑inhibiting properties of other anthracenediones, but it has a distinct toxicity profile, notably a higher risk of cardiotoxicity and secondary leukemia. Compared with anthracyclines, it may be used when resistance to those agents develops, though careful cardiac monitoring remains essential.

Novantrone must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original container until preparation for intravenous infusion, and any unused portion should be discarded according to local regulations.

Novantrone is supplied as an intravenous solution that is infused by a qualified healthcare professional. The infusion rate and duration are determined by the treating physician, typically over a period of several minutes to an hour, depending on the prescribed dose and patient tolerance.

The most serious adverse effects include cardiotoxicity leading to heart failure, the development of secondary acute leukemia, severe hepatic injury, profound neutropenia with risk of life‑threatening infections, and rare but severe hypersensitivity reactions. Continuous monitoring is required to detect these complications early.

Novantrone is contraindicated in patients with known hypersensitivity to mitoxantrone or any component of the formulation, in pregnant women, and in individuals with pre‑existing severe cardiac disease. Caution is also advised for patients with significant hepatic impairment or uncontrolled infections.